Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature

References

• Safina A, Robert B, Frank LP, et al. Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol. 2015;22(12):4014–4019. doi:10.1245/s10434-015-4454-y
   PubMed Web of Science ®Google Scholar
• Masato N, Yuichiro T, William CF, et al. Salivary duct carcinoma: updatesin histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 2020;128(10):693–703. doi:10.1002/cncy.22288
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37(2):125–134. doi:10.1200/JCO.18.00545
   PubMed Web of Science ®Google Scholar
• Fu JY, Wu CX, Shen SK, et al. Salivary gland carcinoma in Shanghai (2003–2012): an epidemiological study of incidence, site and pathology. BMC Cancer. 2019;19(1):350. doi:10.1186/s12885-019-5564-x
   PubMedGoogle Scholar
• Weon YC, Park SW, Kim HJ, et al. Salivary duct carcinomas: clinicaland CT and MR imaging features in 20 patients. Neuroradiology. 2012;54(6):631–640. doi:10.1007/s00234-012-1014-z
   PubMed Web of Science ®Google Scholar
• Schmidt RL, Hall BJ, Layfield LJ. A systematic review and meta-analysis of the diagnostic accuracy of ultrasound-guided core needle biopsy for salivary gland lesions. Am J Clin Pathol. 2011;136(4):516–526. doi:10.1309/AJCP5LTQ4RVOQAIT
   PubMed Web of Science ®Google Scholar
• Nam SJ, Roh JL, Cho KJ, et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol. 2016;23(13):4376–4383. doi:10.1245/s10434-016-5356-3
   PubMed Web of Science ®Google Scholar
• Qian K, Sun W, Guo K, et al. The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: results from the surveillance, epidemiology, and End Results dataset. Eur J Surg Oncol. 2019;45(6):1025–1032. doi:10.1016/j.ejso.2018.11.008
   PubMed Web of Science ®Google Scholar
• Storey MR, Garden AS, Morrison WH, et al. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys. 2001;51(4):952–958. doi:10.1016/s0360-3016(01)01724-2
   PubMed Web of Science ®Google Scholar
• Safdieh J, Givi B, Osborn V, et al. Impact of adjuvant radiotherapy for malignant salivary gland tumors. Otolaryngol Head Neck Surg. 2017;157(6):988–994. doi:10.1177/0194599817717661
   PubMed Web of Science ®Google Scholar
• Brown-Sequard CE. Note on the e_ects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet. 1889;134:105–107. doi:10.1016/S0140-6736(00)64118-1
   Google Scholar
• Claessens F, Denayer S, Tilborgh NV, et al. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal. 2008;6:e008. doi:10.1621/nrs.06008
   PubMedGoogle Scholar
• Tan MH, Li J, Xu HE, et al. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36(1):3–23. doi:10.1038/aps.2014.18
   PubMed Web of Science ®Google Scholar
• Sarker D, Reid AH, Yap TA, et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15(15):4799–4805. doi:10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem. 1991;39(7):927–936. doi:10.1177/39.7.1865110
   PubMed Web of Science ®Google Scholar
• Xu B, Dogan S, Rasheed MRHA, et al. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum Pathol. 2019;93:30–36. doi:10.1016/j.humpath.2019.08.007
   PubMed Web of Science ®Google Scholar
• Liang L, Williams MD, Bell D. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in salivary duct carcinoma. Head Neck Pathol. 2019;13(4):529–534. doi:10.1007/s12105-018-0984-5
   PubMed Web of Science ®Google Scholar
• Locati LD, Quattrone P, Bossi P, et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol. 2003;14(8):1327–1328. doi:10.1093/annonc/mdg331
   PubMed Web of Science ®Google Scholar
• Boon E, Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands.Head. Neck. 2018;40(3):605–613. doi:10.1002/hed.25035
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2016;38(5):724–731. doi:10.1002/hed.23940
   PubMed Web of Science ®Google Scholar
• Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979–984. doi:10.1093/annonc/mdx771
   PubMed Web of Science ®Google Scholar
• Viscuse PV, Price KA, Garcia JJ, et al. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-A Retrospective Study. Front Oncol. 2019;9:701. doi:10.3389/fonc.2019.00701
   PubMed Web of Science ®Google Scholar
• Urban D, Rischin D, Angel C, et al. Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw. 2015;13(3):288–290. doi:10.6004/jnccn.2015.0040
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptorinhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi:10.1038/nrc4016
   PubMed Web of Science ®Google Scholar
• Boxtel WA, Locati LD, Grunsven A, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer. 2019;110:62–70. doi:10.1016/j.ejca.2018.12.035
   PubMed Web of Science ®Google Scholar
• Kuroda H, Sakurai T, Yamada M, et al. Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma. Gan to Kagaku Ryoho. 2011;38(4):627–630.
   PubMedGoogle Scholar
• Soper MS, Iganej S, Thompson LDR. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck. 2014;36(1):E4–7. doi:10.1002/hed.23383
   PubMed Web of Science ®Google Scholar